(Acquisition of treasury stock pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)
Japan, November 5, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its treasury stock pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.
1. Reasons for the acquisition of treasury stock
To improve capital efficiency and enhance return to shareholders.
2. Contents of acquisition
(1) Class of shares to be acquired:
Common stock of the Company
(2) Total number of shares to be acquired:
8.2 million shares (maximum) (The percentage compared to the total number of shares outstanding 1.74%)
(3) Aggregate amount of acquisition cost:
30 billion yen (maximum)
(4) Period of acquisition:
From November 9, 2009 to December 11, 2009
The status of treasury stock as of September 30, 2009:
Total number of shares outstanding: 470,014,807 shares
Number of treasury stock: 5,949,828 shares